Molecular Partners
MOLN
6 hedge funds and large institutions have $13.7M invested in Molecular Partners in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
0.01% more ownership
Funds ownership: 8.87% → 8.88% (+0.01%)
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
3% less capital invested
Capital invested by funds: $14.2M → $13.7M (-$445K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$14.8K |
| 2 |
EWA
EverSource Wealth Advisors
Birmingham,
Alabama
|
+$158 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$1.09K |
MOLN Hedge Fund Activity: Q2 2025 in Review
6 of the 7,610 institutional investors tracked by Wall St. Rank reported a position in Molecular Partners (MOLN) for Q2 2025, worth a combined $13.7M — down 3.1% from $14.2M a quarter earlier.
Fund positioning in MOLN was balanced in Q2 2025: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $14.8K. The largest seller was RhumbLine Advisers, exiting entirely with an estimated $1.09K sold.
- 6 institutional investors held Molecular Partners (MOLN) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $13.7M of Molecular Partners stock for Q2 2025, down 3.1% quarter-over-quarter.
- 1 fund opened new Molecular Partners positions in Q2 2025 and 1 closed out, a net change of 0 holders.
- The largest Molecular Partners buyer in Q2 2025 was UBS Group, an estimated $14.8K added.
- The largest Molecular Partners seller in Q2 2025 was RhumbLine Advisers, an estimated $1.09K sold.
Based on aggregated 13F filings for Q2 2025.